[胃癌患者血清中的抗p53抗体]
[Serum anti-p53 antibodies in gastric cancer patients].
作者信息
Lawniczak Małgorzata, Bielicki Dariusz, Sulzyc-Bielicka Violetta, Marlicz Krzysztof, Starzyńska Teresa
机构信息
Pomorska Akademia Medyczna w Szczecinie, Klinika Gastroenterologii.
出版信息
Pol Merkur Lekarski. 2007 Sep;23(135):192-5.
UNLABELLED
Mutation of the p53 gene belongs to the most common genetic alteration in human cancer. Prognostic significance of serum anti-p53 antibodies in patients with gastric cancer is still a matter of controversy. The aim of the study was to estimate the presence of anti-p53 antibodies in serum of gastric cancer patients and relationship between anti-p53 antibodies and chosen clinical and pathomorphological data age, sex, localization of cancer, histology, stage of disease, metastases to lymph nodes and the time of survival.
MATERIAL AND METHOD
Serum samples from 71 patients with gastric cancer were analyzed by specific enzyme-linked immunosorbent assay (ELISA) to determine the presence of serum anti-p53 antibodies. The results were statistically compared with clinical and pathological features and postoperative survival.
RESULTS
Anti-p53 antibodies were detected in 16 (23%) gastric cancer patients. The presence of p53 antibodies was connected with intestinal tumor type (p < 0.05) and older age (p = 0.0035). There were no association between anti-p53 antibodies, stage and the time of survival.
CONCLUSION
These results suggest that in gastric cancer patients serum anti-p53 antibodies detected by ELISA are not predictor of prognosis.
未标记
p53基因的突变是人类癌症中最常见的基因改变之一。血清抗p53抗体在胃癌患者中的预后意义仍存在争议。本研究的目的是评估胃癌患者血清中抗p53抗体的存在情况，以及抗p53抗体与所选临床和病理形态学数据（年龄、性别、癌症部位、组织学、疾病分期、淋巴结转移和生存时间）之间的关系。
材料与方法
采用特异性酶联免疫吸附测定（ELISA）分析71例胃癌患者的血清样本，以确定血清抗p53抗体的存在情况。将结果与临床和病理特征以及术后生存率进行统计学比较。
结果
在16例（23%）胃癌患者中检测到抗p53抗体。p53抗体的存在与肠型肿瘤（p < 0.05）和年龄较大（p = 0.0035）有关。抗p53抗体、分期和生存时间之间没有关联。
结论
这些结果表明，在胃癌患者中，ELISA检测到的血清抗p53抗体不是预后的预测指标。
Zotero 插件